Structured evidence table for Myo-Inositol Metabolic Health Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Myo-Inositol Metabolic Health Randomized Trial | Conclusion MI-based therapy, particularly early initiation and strategic combinations, should be integrated into multimodal management of PCOS-related cutaneous manifestations. | 2 | Ganjoo A (2026) | Myo-Inositol for Cutaneous Manifestations of Polycystic Ovary Syndrome: An International Delphi Consensus Recommendation for Dermatology Practice. |
| Myo-Inositol Metabolic Health Randomized Trial | Purpose Acne and hirsutism are among the most distressing features of polycystic ovary syndrome (PCOS), yet current guidelines largely emphasize metabolic and reproductive aspects, offering limited guidance for dermatologic management. | 2 | Ganjoo A (2026) | Myo-Inositol for Cutaneous Manifestations of Polycystic Ovary Syndrome: An International Delphi Consensus Recommendation for Dermatology Practice. |
| Myo-Inositol Metabolic Health Randomized Trial | Myo-inositol (MI), an insulin-sensitizing agent with endocrine benefits, has emerged as a promising nonhormonal option; however, its role in managing cutaneous symptoms remains unclear. | 2 | Ganjoo A (2026) | Myo-Inositol for Cutaneous Manifestations of Polycystic Ovary Syndrome: An International Delphi Consensus Recommendation for Dermatology Practice. |
| Myo-Inositol Metabolic Health Randomized Trial | Anxiety and depressive disorders frequently co-occur, and converging evidence from symptom profiles, longitudinal course, shared neurobiological markers, familial aggregation, and treatment response supports a substantial overlap between these conditions []. | 4 | Derkaczew Maria (2026) | Potential Anxiolytic Effects of Selected Inositol Stereoisomers—A Narrative Review |
| Myo-Inositol Metabolic Health Randomized Trial | Importantly, even agents considered comparatively “benign”, such as non-benzodiazepine anxiolytics, may rarely cause significant neurological adverse effects in vulnerable individuals, as illustrated by reports of buspirone-associated dyskinesia or dystonia, plausibly related to its interactions with dopaminergic signaling []. | 4 | Derkaczew Maria (2026) | Potential Anxiolytic Effects of Selected Inositol Stereoisomers—A Narrative Review |
| Myo-Inositol Metabolic Health Randomized Trial | Recent reports have also raised the possibility that selected cyclitols may exert anxiolytic activity; however, robust clinical evidence remains scarce, and the available data are largely preliminary, often derived from indirect observations or preclinical research []. | 4 | Derkaczew Maria (2026) | Potential Anxiolytic Effects of Selected Inositol Stereoisomers—A Narrative Review |
| Myo-Inositol Metabolic Health Randomized Trial | 1 2 3 4 1 Anxiety plays a dual role, encompassing both adaptive and maladaptive dimensions. | 4 | Derkaczew Maria (2026) | Potential Anxiolytic Effects of Selected Inositol Stereoisomers—A Narrative Review |
Source documents